Imagine if multiple sclerosis (MS) became as rare as polio. It sounds absurd. MS is chronic, unpredictable, and devastating. We’ve spent decades throwing immunosuppressants, monoclonal antibodies, and remyelination therapies at it. But no matter how advanced our treatments have become, they all manage the disease, not the cause. That might be about to change.

Researchers from the Garvan Institute of Medical Research have conducted an unprecedented analysis of over 1.25 million blood cells from nearly 1,000 participants to elucidate why women experience higher rates of autoimmune diseases. Using single-cell RNA sequencing, the team identified over 1,000 genetic switches in immune cells that function differently based on sex. These variations in gene expression indicate that inflammatory pathways responding to threats are more active in women, increasing susceptibility to conditions such as lupus and multiple sclerosis. The findings underscore the critical importance of incorporating sex-based considerations into immune system research and clinical treatment development. This pioneering study addresses a significant gap in medical research by examining individual cell-level differences rather than averaging gene activity across mixed cell populations, potentially revolutionizing our understanding of sex-specific disease mechanisms.

Researchers from the Garvan Institute and UNSW Sydney have identified over 1,000 genetic switches that function differently between female and male immune cells, providing crucial insights into why women are significantly more susceptible to autoimmune diseases such as lupus and multiple sclerosis. The study, published in The American Journal of Human Genetics, reveals that female immune systems exhibit higher inflammatory pathway activity, making them more prone to mistakenly attacking healthy body tissues. These findings underscore a critical gap in medical research, which has historically focused on male cohorts, and emphasize the necessity of considering sex differences in understanding disease mechanisms and developing effective treatments.

Researchers from Yale School of Medicine have identified a genetically driven immunologic mechanism linking Epstein-Barr virus (EBV) infection to multiple sclerosis development. This collaborative study, involving international institutions, elucidates how genetic factors predispose individuals to MS through EBV-triggered immune responses. The findings represent a significant advancement in understanding the molecular basis of MS pathogenesis, potentially opening new therapeutic avenues for prevention and treatment. By establishing this mechanistic link between viral infection and autoimmune disease, the research contributes valuable insights into how environmental and genetic factors converge in neurological disease development.

Cell therapy represents a promising therapeutic approach for multiple sclerosis, offering potential mechanisms to repair neurological damage and modulate immune dysfunction. This comprehensive overview examines the current state of cell-based treatments in MS management, including various cell types and their therapeutic applications. The review synthesizes existing evidence regarding efficacy, safety profiles, and clinical outcomes associated with cellular interventions. By exploring the immunological and regenerative properties of different cell therapies, this article provides healthcare professionals and researchers with essential insights into emerging treatment modalities that may complement or enhance conventional MS therapies, ultimately advancing patient care and clinical outcomes.

Recent research has established Epstein-Barr virus as a pivotal factor in multiple sclerosis pathogenesis. Dr. Micah Luftig presents mechanistic insights into the EBV-MS relationship, highlighting its significance for clinical risk stratification and early intervention strategies. The emerging evidence suggests that EBV-targeted therapeutic approaches may fundamentally reshape future MS treatment protocols. Understanding the molecular mechanisms linking viral infection to neuroinflammatory cascade activation is crucial for developing preventive and therapeutic interventions. These findings have substantial implications for clinicians managing MS patients and may inform personalized medicine approaches based on individual EBV serostatus and immune profiles.

Researchers found that CUX2 neurons are especially sensitive to damage caused by inflammation. In diseases like MS, the body’s immune system attacks the brain, leading to long-term damage. While MS has been thought to primarily affect white matter in the brain, this research shows that it could also damage particularly vulnerable CUX2 neurons in the gray matter.This damage may help explain why people with MS can experience memory problems and cognitive decline as the disease progresses.“The CUX2 neurons are like a ‘canary in the coal mine’ for the brain affected by MS,” said David Rowitch, MD, PhD, co-corresponding author of both studies, deputy director for Research at Guerin Children’s, and professor of Paediatrics at the University of Cambridge. “They are early warning signs of trouble. If we can protect these cells, we might be able to contain the damage before disease progresses.”

For years, scientists have suspected that the gut plays a role in Multiple Sclerosis (MS), but the “smoking gun” linking the two has been elusive. A landmark study has finally identified the cellular mechanism: Intestinal Epithelial Cells (IECs)—the cells lining your gut—are acting as “accidental” messengers.The study found that in patients with MS, these gut cells abnormally express MHC II, a protein that “presents” antigens to the immune system. This interaction mistakenly transforms ordinary immune cells into pathogenic Th17 cells, which then migrate from the gut directly to the central nervous system to attack the brain and spinal cord.

Researchers from UC San Francisco, the University of Cambridge, and Cedars-Sinai Medical Center now report that this loss is linked to DNA damage inside neurons, driven by inflammation in the brain. The discovery helps explain why scans of people with MS show injury not only in white matter, which carries signals, but also in gray matter, where brain cells reside. It also points to new treatment possibilities.

A gene on the X chromosome revs up inflammation in the female brain, which may explain why rates of multiple sclerosis are higher in women than in men, scientists suggest.

Progressive multiple sclerosis (PMS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) characterized by relentless progression and limited treatment options. Recent studies have highlighted the role of B cells and plasma cells in driving PMS but current therapies face challenges in targeting cells within the CNS. Now, writing in Cell, Qin et al. present a first-in-human study of anti-B cell maturation antigen (BCMA) chimeric antigen receptor T (CAR-T) cell therapy in five patients with PMS, showing a favourable safety profile and potential therapeutic benefits.

Près de deux millions de personnes dans le monde souffrent de cette maladie invalidante. Les symptômes varient énormément, et il n'y a aucun remède connu à ce jour.

Pendant des décennies, les scientifiques ont accumulé des indices pointant vers le virus Epstein-Barr. Présent dans l’organisme de plus de 90% des adultes à travers le monde, ce virus de la famille des herpès est connu pour provoquer la mononucléose infectieuse. Or, plusieurs études avaient déjà observé une surreprésentation de cette infection dans les antécédents des patients atteints de sclérose en plaques. La corrélation intrigue, mais reste difficile à interpréter tant le virus circule largement dans la population générale.

Multiple sclerosis (MS) is among the most common causes of disability in the young and, despite the advent of highly effective disease-modifying therapies, remains an incurable disease. Prevention of MS before the onset of demyelination is a feasible, albeit ambitious, goal. Currently, preventive interventions with adequate evidence of efficacy are lacking, and evaluating such interventions with traditional trial designs is challenging. Additionally, the high frequency and low effect sizes of putative MS risk factors, a limited window of opportunity to intervene, and the relatively low incidence of MS in the general population make prevention studies conceptually and practically difficult.

While MS is a chronic condition, its progression isn't uniform or predictable. Some people experience minimal progression over many years, while others may face more rapid changes. Let's explore the factors that influence MS progression and what current research tells us about managing the condition.

Multiple sclerosis (MS) stands out as one of the most prevalent causes of disability among young adults, placing immense pressure on healthcare systems and affecting the quality of life for those affected. Despite advancements in therapies that modify the course of the disease, MS has yet to be declared curable. This presents an ongoing challenge for researchers and clinicians alike. The focus is now shifting toward the ambitious—but indeed feasible—goal of preventing MS before any symptoms or demyelination occur. However, the path to achieving this presents numerous methodological challenges that call for innovative thinking.

MS is a chronic autoimmune disease affecting the CNS over a long-term period. The severity of MS varies widely and is influenced by several factors, comprising the endocrine activity of AT. The involvement of AT in MS pathogenesis remains to be further clarified; certainly, MS is characterized by an altered immune response in which AT also participates through dysregulated adipokine secretion, increasing the risk of disease development and accelerating its progression. Based on the data presented in this review, it is plausible that the functionality of AT is positively influenced by lifestyle factors such as physical activity and nutrition, which are essential in the management of MS.

Researchers revealed a pivotal mechanism in myelin repair and regeneration, focusing on the Daam2 protein and CK2α kinase. Myelin, critical for efficient neurotransmission, when damaged leads to serious neurological diseases. Their findings spotlight the Wingless (Wnt) signaling pathway, crucial for myelin regeneration. Unveiling how Daam2 inhibits myelination, this study offers hope for untreatable neurological conditions.

Pour la première fois, un élément crucial de la progression de la maladie vient d'être mis au jour : le premier variant génétique associé à une sévérité accrue de la sclérose en plaques. Dans l'ADN, les variants sont des changements permanents sur les gènes. On les appelle des "polymorphismes" lorsque ces changements sont fréquents dans la population ou des "mutations" lorsque le changement est rare. Peu importe leur nature, les variants, de par les modifications qu'ils entraînent dans l'ADN, peuvent être à l'origine de maladies.

Alors que la sclérose en plaques demeure aujourd’hui incurable, une équipe de neuroscientifiques de l’Université de Virginie a fait une découverte majeure, qui pourrait changer la vie des malades. Ils ont en effet identifié le récepteur cellulaire qui provoque la réponse auto-immune et la neuroinflammation caractéristiques de la maladie. Il pourrait s’agir d’une nouvelle cible de choix pour la mise au point de nouveaux traitements.